NCT06456450

Taiwan Severe Asthma Biologic Registry

• Status: Recruiting
• Phase: —
• Study type: Observational
• Enrollment: 500 (estimated)
• Sponsor: Taichung Veterans General Hospital · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This is a prospective multi-centers cohort study for registration adult patients with severe asthma and were reimbursed biologics treatment in Taiwan. The goal of this observational study is to discover the real-world effectiveness, the impact of initiating, switching of biologics, and the possible prediction factors for selecting the best treatment option for patients. The main question\[s\] it aims to answer are: 1. Determine risk factors associated with poor asthma control. 2. Support the development of effectiveness and safety of therapeutic principles 3. To discover the real-world effectiveness of different biologics ( Clinical remission) 4. To discover the impact of initiating biologics for severe asthma patients. 5. To evaluate the prevalence of biologics switching and its benefits for patients. 6. To compare the achievement rate of clinical remission among different biologics. Participants who are treated either with omalizumab, mepolizumab, benralizumab dupilzumab or Tezepelumab after January 1, 2020 will be included in the study.

Conditions

• Pulmonary Disease
• Asthma

Interventions

Type	Name	Description
BIOLOGICAL	Biological Treatment for severe asthma patients	Biological treatment for severe asthma available in Taiwan and is covered by covered by National Health Insurance

Timeline

• Start date: 2023-11-11
• Primary completion: 2043-02-28
• Completion: 2043-02-28
• First posted: 2024-06-13
• Last updated: 2024-06-13

Locations

1 site across 1 country: Taiwan